Supernus granted fifth patent for epilepsy drug

Supernus Pharmaceuticals Inc. on Tuesday received its fifth patent covering Oxtellar XR, its novel once-daily, extended-release oxcarbazepine product.

Supernus markets two products for epilepsy: Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate). 

Oxtellar XR is the first approved novel, oral, once-daily extended release formulation of oxcarbazepine for the treatment of epilepsy. Oxtellar XR is indicated for adjunctive therapy in the treatment of partial seizures in adults and in children 6 to 17 years of age. The product is available in 150mg, 300mg, and 600mg extended-release tablets.

"We are very serious about securing intellectual property protection for our innovative products,” Supernus CEO and President Jack Khattar said. “We will continue to build our patent estate to provide our products with the protection they are entitled to. We now have patent protection on Oxtellar XR and Trokendi XR through five and six issued U.S. patents, respectively.”

The patent provides protection for Oxtellar with an expiration date no earlier than 2027. 

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company is also developing product candidates to address large market opportunities in psychiatry.